Value-based analysis of drug policy impact on the strategic development goals of the Russian Federation

Ценностно-ориентированный анализ влияния политики в области лекарственного обеспечения на достижение основных целей развития Российской Федерации

Nazarov, Vladimir (Назаров, Владимир) (), Avxentyev, Nikolay (Авксентьев, Николай) () and Sisigina, Natalia (Сисигина, Наталья) ()
Additional contact information
Nazarov, Vladimir (Назаров, Владимир): The Russian Presidential Academy of National Economy and Public Administration
Avxentyev, Nikolay (Авксентьев, Николай): The Russian Presidential Academy of National Economy and Public Administration
Sisigina, Natalia (Сисигина, Наталья): The Russian Presidential Academy of National Economy and Public Administration

Working Papers from Russian Presidential Academy of National Economy and Public Administration

Abstract: Relevance. In recent years, several projects have been proposed to expand the state guarantees for the provision of drugs to patients with specific diseases. However, none of them have been fully implemented. The inconsistency in expanding medicinal guarantees might be linked to the lack of unified approaches to justify the need for additional drug supply. Objective. Development of a methodology for assessing the reserves for achieving the main health development goals of the Russian Federation by expanding drug provision to patients with priority disease groups. Novelty. Development of an original econometric model based on real-world evidence. Methods. Regression analysis of mortality using «fixed» and «between» effects models. The dependent variable was the standardized mortality rate for specific causes. Independent variables included drug coverage of target study population and factors representing external influences (such as the availability of primary healthcare resources, socio-economic population characteristics, and environmental quality). Results. For immuno-oncological drugs, a 1 percentage point increase in drug coverage is associated with a 0.4% reduction in the standardized cancer mortality rate. If drug coverage expands to 100%, a projected decrease in mortality by 9,005 individuals is expected. Conclusions. Model validation using immuno-oncological therapy as an example confirmed the possibility of measuring the potential beneficial effect of expanding drug provision based on real-world data.

Keywords: drugs access; immuno-oncological drugs; drug provision; oncological diseases; healthcare policy; healthcare expenditure; mortality (search for similar items in EconPapers)
JEL-codes: I18 (search for similar items in EconPapers)
Pages: 46 pages
Date: 2023
References: Add references at CitEc
Citations:

Downloads: (external link)
https://repec.ranepa.ru/rnp/wpaper/w202363.pdf

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:rnp:wpaper:w202363

Access Statistics for this paper

More papers in Working Papers from Russian Presidential Academy of National Economy and Public Administration Contact information at EDIRC.
Bibliographic data for series maintained by RANEPA maintainer ().